tetano
Editor, Senior Moderator
Front Immunol
. 2021 Nov 24;12:700705.
doi: 10.3389/fimmu.2021.700705. eCollection 2021.
Activation of Intracellular Complement in Lungs of Patients With Severe COVID-19 Disease Decreases T-Cell Activity in the Lungs
Mark C Howell[SUP] 1 2 [/SUP], Ryan Green[SUP] 1 2 [/SUP], Andrew R McGill[SUP] 1 2 3 [/SUP], Roukiah M Kahlil[SUP] 3 [/SUP], Rinku Dutta[SUP] 3 [/SUP], Shyam S Mohapatra[SUP] 1 3 [/SUP], Subhra Mohapatra[SUP] 2 3 [/SUP]
Affiliations
Abstract
A novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), arose late in 2019, with disease pathology ranging from asymptomatic to severe respiratory distress with multi-organ failure requiring mechanical ventilator support. It has been found that SARS-CoV-2 infection drives intracellular complement activation in lung cells that tracks with disease severity. However, the cellular and molecular mechanisms responsible remain unclear. To shed light on the potential mechanisms, we examined publicly available RNA-Sequencing data using CIBERSORTx and conducted a Ingenuity Pathway Analysis to address this knowledge gap. In complement to these findings, we used bioinformatics tools to analyze publicly available RNA sequencing data and found that upregulation of complement may be leading to a downregulation of T-cell activity in lungs of severe COVID-19 patients. Thus, targeting treatments aimed at the modulation of classical complement and T-cell activity may help alleviate the proinflammatory effects of COVID-19, reduce lung pathology, and increase the survival of COVID-19 patients.
Keywords: T-cells; bioinformatics; complement; lungs; severe COVID-19 disease.
. 2021 Nov 24;12:700705.
doi: 10.3389/fimmu.2021.700705. eCollection 2021.
Activation of Intracellular Complement in Lungs of Patients With Severe COVID-19 Disease Decreases T-Cell Activity in the Lungs
Mark C Howell[SUP] 1 2 [/SUP], Ryan Green[SUP] 1 2 [/SUP], Andrew R McGill[SUP] 1 2 3 [/SUP], Roukiah M Kahlil[SUP] 3 [/SUP], Rinku Dutta[SUP] 3 [/SUP], Shyam S Mohapatra[SUP] 1 3 [/SUP], Subhra Mohapatra[SUP] 2 3 [/SUP]
Affiliations
- PMID: 34899680
- PMCID: PMC8652259
- DOI: 10.3389/fimmu.2021.700705
Abstract
A novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), arose late in 2019, with disease pathology ranging from asymptomatic to severe respiratory distress with multi-organ failure requiring mechanical ventilator support. It has been found that SARS-CoV-2 infection drives intracellular complement activation in lung cells that tracks with disease severity. However, the cellular and molecular mechanisms responsible remain unclear. To shed light on the potential mechanisms, we examined publicly available RNA-Sequencing data using CIBERSORTx and conducted a Ingenuity Pathway Analysis to address this knowledge gap. In complement to these findings, we used bioinformatics tools to analyze publicly available RNA sequencing data and found that upregulation of complement may be leading to a downregulation of T-cell activity in lungs of severe COVID-19 patients. Thus, targeting treatments aimed at the modulation of classical complement and T-cell activity may help alleviate the proinflammatory effects of COVID-19, reduce lung pathology, and increase the survival of COVID-19 patients.
Keywords: T-cells; bioinformatics; complement; lungs; severe COVID-19 disease.